Figure 5.

Vancomycin effects on neuronal or macrophage density are abrogated in mice deficient in bone-marrow-derived macrophage recruitment. (A) Representative density plots of singlet CD45⁺ CX₃CR1⁺ CD11b⁺ F4/80+ cells from control and vancomycin-treated CCR2-deficient mice, respectively. There was a decrease in CD45⁺ CX₃CR1⁺ CD11b⁺ F4/80⁺ cells in vancomycin-treated CCR2-deficient mice when compared with controls by (B) percentage (control 0.86% ± 0.71% of total cells, n = 4; vancomycin 0.13% ± 0.18% of total cells, n = 6), but there was no change in the (C) absolute number of cells (control 2,360 ± 1,483 cells, n = 4; vancomycin 1,702 ± 1,955 cells, n = 6). (D, E) Colonic myenteric plexus stained for neurons with HuC/D in CCR2-deficient control and vancomycin-treated pups. Scale bar = 50 µm. (F) Quantification of neurons/HPF demonstrated an increase in neuronal density in vancomycin-treated CCR2-deficient mice compared with controls (control 236.7 ± 90.9 neurons/HPF, n = 10; vancomycin 322.9 ± 71 neurons/HPF, n = 11).